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Molecular and Cellular Pathobiology
miR-23b Represses Proto-oncogene Src Kinase and
Functions as Methylation-Silenced Tumor Suppressor with
Diagnostic and Prognostic Signiﬁcance in Prostate Cancer
Shahana Majid1, Altaf A. Dar2, Sharanjot Saini1, Sumit Arora1, Varahram Shahryari1, Mohd Saif Zaman1,
Inik Chang1, Soichiro Yamamura1, Yuichiro Tanaka1, Guoren Deng1, and Rajvir Dahiya1
Abstract
The miRNAs have great potential as biomarkers and therapeutic agents owing to their ability to control
multiple genes and potential to inﬂuence cellular behavior. Here, we identiﬁed that miR-23b is a methylation-
silenced tumor suppressor in prostate cancer. We showed that miR-23b expression is controlled by promoter
methylation and has great promise as a diagnostic and prognostic biomarker in prostate cancer. High levels of
miR-23b expression are positively correlated with higher overall and recurrence-free survival in patients with
prostate cancer. Furthermore, we elucidated the tumor suppressor role of miR-23b using in vitro and in vivo
models.We showed that proto-oncogene Src kinase andAkt are direct targets ofmiR-23b. Increased expression of
miR-23b inhibited proliferation, colony formation, migration/invasion, and triggered G0–G1 cell-cycle arrest and
apoptosis in prostate cancer. Overexpression of miR-23b inhibited epithelial-to-mesenchymal transition (EMT)
causing a decline in mesenchymal markers Vimentin and Snail and increasing the epithelial marker, E-cadherin.
Depletion of Src by RNA interference conferred similar functional effects as that of miR-23b reconstitution. miR-
23b expression caused a dramatic decrease in tumor growth in nude mice and attenuated Src expression in
excised tumors compared with a control miR. These ﬁndings suggest that miR-23b is a methylation-silenced
tumor suppressor that may be a useful biomarker in prostate cancer. Loss of miR-23b may confer proliferative
advantage and promote prostate cancer migration and invasion, and reexpression of miR-23b may contribute to
the epigenetic therapy for prostate cancer. Cancer Res; 72(24); 6435–46. 2012 AACR.
Introduction
Prostate cancer is the most frequently diagnosed malig-
nant tumor and second leading cause of cancer deaths in
American men. It is estimated that 240, 890 newly diagnosed
prostate cancer cases and 33,720 attributed deaths will occur
in 2011 (1). Current prostate cancer treatments consisting of
malignant prostate ablation by radical prostatectomy, radio-
therapy, hormonal therapy, and/or neoadjuvant chemother-
apy are generally curative for the majority of patients
diagnosed with localized and androgen-dependent prostate
cancer. However, progression to androgen-independent and
metastatic disease states is often accompanied by a recur-
rence of prostate cancer and treatment remains a clinical
challenge (2, 3).
The miRNAs are non–protein-coding sequences thought to
regulate more than 90% of human genes (4). Growing evidence
has strongly implicated the involvement of miRNAs in carci-
nogenesis (5, 6). From a clinical point of view, miRNAs have
great potential as diagnostic and therapeutic agents. Micro-
array analysis has shown a general downregulation of miRNAs
in tumors when compared with normal tissues (7). Owing to
the tissue speciﬁcity ofmiRNAs, they have become a useful tool
for deﬁning the origin of tumors in poorly differentiated
cancers (8). Prognosis and survival of patients depends on the
cancer stage at diagnosis. For this reason, an important issue in
clinical cancer research is to identify early biomarkers of the
early tumorigenic process. miRNA signatures have been
reported to be useful tools for early diagnosis of cancer (9, 10).
DNA hypermethylation of CpG sites within CpG islands is
known to lead to the inactivation of many tumor-suppressive
miRNAs (11). One of the most common causes of the loss for
tumor suppressor miRNAs is silencing of their primary tran-
scripts by CpG island hypermethylation (12–16). The DNA
methylation proﬁle of tumors is useful to deﬁne tumor type,
clinical prognosis, and treatment response (17, 18). Epigenetic
silencing of miRNAs is also involved in the acquisition of an
invasive phenotype and the development of metastasis (19).
Inactivation of oncogenic miRNAs (20, 21) or restoration of
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tumor suppressor miRNAs (12–14) has great potential for
cancer treatment.
Here, we report that (i) miR-23b is frequently silenced
through tumor-speciﬁc DNA methylation in prostate cancer,
(ii) miR-23b acts as a tumor suppressor miRNA and has
diagnostic/prognostic implication in prostate cancer, (iii)
miR-23b directly targets proto-oncogene Src kinase and Akt,
(iv) miR-23b has anti-proliferative/-migratory/-invasive effects
by downregulating molecules involved in these pathways, (v)
miR-23b inhibits epithelial-to-mesenchymal transition (EMT)
markers, and (vi) miR-23b decreased in vivo tumor growth and
Src kinase expression in nude mice xenografts.
Materials and Methods
Cell culture, plasmids, and probes/primers
Human prostate cancer cell lines PC3, DU145, LNCaP and a
nonmalignant prostate cell line RWPE1 were obtained from
the American Type Culture Collection (ATCC) and grown
according to ATCC protocol. These human-derived cell lines
were authenticated by DNA short-tandem repeat analysis by
ATCC. The experiments with cell lines were carried out within
6 months of their procurement/resuscitation. Plasmids pEZX-
MT01 miRNA 30-untranslated region (UTR) target expression
clones for Src (HmiT017696-MT01), AKT (HmiT004995-MT01)
and miRNA Target clone control vector for pEZX-MT01
(CmiT000001-MT01) were purchased from GeneCopoeia. Taq-
Man probes for hsa-miR-23b (miR-23b) and negative control
pre-miR were purchased from Applied Biosystems. siRNA
duplexes [(Src (Human)-3 unique 27mer siRNA duplexes
(SR304574)] were purchased from Origene Technologies, Inc.
Quantitative real-time PCR
Tissue samples from radical prostatectomy were obtained
from the Veterans Affairs Medical Center (San Francisco, CA).
Total RNA was extracted and assayed for mature miRNAs and
mRNAs using the TaqManMicroRNAAssays andGene Expres-
sion Assays, respectively, in accordance with the manufac-
turer's instructions (Applied Biosystems). All real-time reac-
tions were run in a 7500 Fast Real Time PCR system (Applied
Biosystems). Relative expression was calculated using the
comparative Ct.
Methylation analysis of miR-23b by quantitative
methylation-speciﬁc PCR
To investigate the mechanism involved in reduced levels of
miR-23b in prostate cancer, we conducted methylation anal-
ysis in the 1.0-kb upstream sequence of miR-23b. Two CpG
islands: CG-1 (120 to 3 bp) and CG-2 (820 to 650 bp)
were located in 1.0 kb upstream sequence and further analyzed
formethylation status in cell lines and tissue samples. DNAwas
available only for 38 (19 pairs) of laser-capturedmicrodissected
(LCM) tissue samples, and these samples were from the same
cohort of 118 samples for which RNA expression was available.
DNA was bisulfate-converted using EZ DNAMethylation-Gold
Kit (ZymoResearch) according to themanufacturer's protocol.
The converted DNA was ampliﬁed by PCR with 400 pmol/L of
either primer set F1/R1, or F2/R2, and HotStar Taq Plus DNA
Polymerase (Qiagen). PCR was carried out by denaturation at
95C for 5minutes, followed by 15 cycles of 94C for 30 seconds,
56C for 30 seconds, and 72C for 30 seconds. Two microliters
of the PCR product was added to 40 mL solution containing 20
mL TaqMan Fast Universal PCR Master Mix (2; Applied
Biosystems), 500 pmol/L primers F1/R1 or F2/R2. The mixed
solution was aliquoted evenly into 2 tubes and was added 1 mL,
5 mmol/L probe for methylation reaction (PM) probe for
methylation (M) reaction and 1 mL, 5 mmol/L probe for
unmethylation reaction (PU) probe for unmethylation (U)
reaction, respectively. Methylation in CGI-1 and CGI-2 was
measured by quantitative real-time PCR (qRT-PCR) with an
Applied Biosystems 7500 Fast Sequence Detection. For each
sample, the percentage of methylation was calculated by the
difference of Ct inM reaction (Ct_M) andCt in U reaction (Ct_U).
In situ hybridization
In situ hybridization (ISH) was conducted as described
previously (22). Brieﬂy, cell lines and tissues were stained using
DIG-labeled locked nucleic acid (LNA)-based probes speciﬁc
for mir-23b and U6 following the manufacturer's protocol
(Exiqon, Inc.) and detected using anti-DIG-Fluorescein, Fab
Fragments (Roche Applied Science for cell lines and BMPurple
AP Substrate (Roche Applied Science) for tissues. ISH results
for tissue array were graded according to quick score (per-
centage of cells stained intensity of stain) and normalized to
U6 levels.
Flow cytometry, cell viability, migration, clonability, and
invasion assays
Fluorescence-activated cell-sorting (FACS) analysis for cell
cycle and apoptosis was done 72 hours posttransfection using
nuclear stain, 40,6-diamidino-2-phenylindole (DAPI), for cell-
cycle analysis or Annexin V-FITC/7-AAD Kit (Beckman Coul-
ter, Inc.) for apoptosis analysis according to themanufacturer's
protocol. Cell viability was determined at 24, 48, and 72 hours
by using the CellTiter 96 AQueous One Solution Cell Prolifer-
ation Assay Kit (Promega) according to the manufacturer's
protocol. For colony formation assay, cells were seeded at low
density (1,000 or 200 cells per plate) and allowed to grow until
visible colonies appeared. Then, cells were stainedwithGiemsa
and colonies were counted. Cytoselect 24-well cell migration
and invasion assay kit (Cell Biolabs, Inc.) was used for migra-
tion and invasion assays according tomanufacturer's protocol.
Immunoblotting and immunoﬂuorescence
Immunoblotting was conducted as described previously
(23). The antibodies used were speciﬁc for Src (2123; Cell
Signaling), pSrc (2101; Cell Signaling), MEK1/2 (4694; Cell
Signaling), pMEK1/2 (Ser217/221; 9154; Cell Signaling), p44/
42 MAPK (Erk1/2; 4695; Cell Signaling), p-p44/42 MAPK
(Thr2021/Tyr204; 4370; Cell Signaling), STAT3 (9132), p-STAT3
(Tyr705; 9145; Cell Signaling), Akt (4685; Cell Signaling), p-Akt
(Ser473; 4060; Cell Signaling), Bad (9292; Cell Signaling), p-Bad
(Ser136; 4366; Cell Signaling), FAK (3285; Cell Signaling), c-Jun
(9165; Cell Signaling), and GAPDH (sc-32233; Santa Cruz Bio-
technology, Inc.). Blots were visualized using Western blotting
luminal reagent (sc-2048; Santa Cruz Biotechnology, Inc.).
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For immunoﬂuorescence, cells were transfected with pre-
cursors ofmiR-23b or cont-miR for 72 hours, washed, and ﬁxed
with acetone-methanol (1:1) mixture and hybridized with the
speciﬁc primary antibodies against EMT markers. Cells were
washed and hybridizedwith ﬂuorescein-conjugated secondary
antibody (1:1,000) and mounted with ProLong Gold antifade
reagent with DAPI (Invitrogen Life Technologies).
Luciferase assays
The complimentary sites in 30UTR of Src and Akt for miR-
23b and mutated sequences are given in Supplementary Table
S7. The Src, Akt, and control vectors were purchased from
GeneCopoeia and named Src-30UTR and Akt 30UTR. Mutated
30UTR sequences of Src and Akt were cloned and named Mut
Src30UTR and Mut Akt30UTR. For reporter assays, cells were
transiently transfected with wild-type or mutated reporter
plasmid and miR-23b or control-miR. Fireﬂy luciferase activ-
itiesweremeasured using theDual Luciferase Assay (Promega)
18 hours after transfection, and the results were normalized
with Renilla luciferase. Each reporter plasmid was transfected
at least 3 times, and each sample was assayed in triplicate.
In vivo intratumoral delivery of miR-23b and genistein
The antitumor effect of miR-23b was determined by local
administration of miR-23b precursor in established tumors.
Each mouse was injected subcutaneously with 5.0  106 PC3
prostate cancer cells. Once palpable tumors developed (aver-
age volume¼ 55 mm3), 6.25 mg of synthetic miRNA complexed
with 1.6 mL siPORT Amine transfection reagent (Ambion) in 50
mL PBS was delivered 8 times intratumorally at 3-day intervals.
Tumor growthwas followed for 21 days from the ﬁrst injection.
All animal care was in accordance with the institutional
guidelines.
Statistical analysis
Statistical analyses were conducted with StatView for Win-
dows (SAS Institute Inc.), GraphPad-Prism5 and MedCalc. All
quantiﬁed data represent average of at least triplicate samples
or as indicated. Error bars represent SD of mean. All tests
conducted were 2-tailed, and P < 0.05 was considered statis-
tically signiﬁcant. Receiver-operating curves (ROC) were cal-
culated to determine potential ofmiR-23b or itsmethylation to
discriminate between malignant and nonmalignant samples.
The c2 tests were conducted to determine correlation between
miR-23b expression and clinicopathologic characteristics. For
disease progression analysis, Kaplan–Meier approach (log-
rank test) and multiple regression analysis were conducted.
Results
miR-23b is signiﬁcantly downregulated in prostate
cancer
To identify silenced miRNAs in prostate cancer, we con-
ducted microarray screening using cancer cell lines and a
nonmalignant cell line. Mir-23b was found to be a signiﬁcantly
downregulated miRNA in cancer compared with the nonma-
lignant cell line. We validated the microarray data by miRNA
qRT-PCR analysis. The results conﬁrmed that miR-23b was
downregulated in cancer cell lines (Fig. 1A). In situ hybridiza-
tion also conﬁrmed the presence of miR-23b expression (green
signal) in RWPE1 cells compared with cancer cell lines (Fig.
1B). DU145 cells express higher levels of miR-23b but the
green signal is absent because we have to keep the exposure
time same across the cell lines. To examine the biologic
signiﬁcance of miR-23b, its expression was analyzed by
qRT-PCR in 236 (118 pairs) LCM matched tissue samples
(Fig. 1C; Supplementary Fig. S1) and an unmatched group of
27 benign prostatic hyperplasia (BPH) and 20 tumor samples
(Fig. 1D) along with another cohort of 48 samples where
expression was analyzed by ISH (Fig. 1E). Among all samples,
miR-23b expression was signiﬁcantly downregulated in can-
cer samples compared with normal or BPH (Fig. 1C–E). These
results indicate a putative tumor suppressor role of miR-23b
in prostate cancer.
Diagnostic and prognostic signiﬁcance of miR-23b in
prostate cancer
Clinical demographics of the study cohort are summarized
in Supplementary Table S1. ROC analyses were conducted to
evaluate the ability of miR-23b expression to discriminate
between normal and tumor cases using 151 pairs of tissue
samples. An area under the ROC curve (AUC) of 0.975 [P <
0.0001; 95% conﬁdence interval (CI), 0.950–0.999; Fig. 2A] was
obtained, suggesting thatmiR-23b expression can discriminate
between malignant and nonmalignant samples and hence can
be used as a diagnostic marker for prostate cancer. To deter-
mine whether miR-23b has any prognostic signiﬁcance, we
divided 151 cases into low miR-23b [expression tumor (T)/
normal (N) < 0.8-fold] and highmiR-23b (expression T/N > 0.8-
fold) groups and conducted Kaplan–Meier survival analysis
andmultiple regression analysis. In Kaplan–Meier analysis, the
miR-23b high group displayed signiﬁcantly higher overall
survival (OS) probability than themiR-23b low group (log-rank
test: P < 0.0001; HR, 3.3; 95% CI, 4–19; Fig. 2B). Kaplan–Meier
survival analysis for recurrence-free survival (RFS) was con-
ducted using 105 cases. Cases with high miR-23b expression
had better RFS than with low miR-23b expression cases (log-
rank test: P < 0.002; HR, 6; 95% CI, 3–13; Fig. 2C). We conducted
multiple regression analysis for the same set of patients using
entry, forward, backward, and stepwise methods one by one
(Supplementary Tables S2–S5). Multiple regression analysis
revealed that miR-23b expression is an independent predictor
of biochemical recurrence (P < 0.02) as determined in entry,
forward, backward and stepwise methods (Supplementary
Table S2). We also determined the correlation of miR-23b
expression with clinicopathologic variables such as Gleason
grade, pathologic stage (pT), and biochemical recurrence (Fig.
2D) and details are described in detail in Supplementary
Results. Correlation tests revealed that cases with low miR-
23b expression increased from low-grade, low pathologic stage
to high-grade and high pathologic stage (Fig. 2D). Patients who
had prostate-speciﬁc antigen (PSA) recurrence also had sig-
niﬁcantly lowmiR-23b expression. These ﬁndings suggest that
miR-23b has a potential to be a diagnostic and prognostic
marker for predicting the biochemical recurrence of patients
with prostate cancer, although addition of more samples may
strengthen these results.
miR-23b in Prostate Cancer
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Mechanism of silencing of miR-23b in prostate cancer is
through CpG hypermethylation: correlation between
miR-23b methylation status with expression and use as
diagnostic marker
Two CpG islands, CG-1 and CG-2, were located in 1.0 kb
upstream sequence (Fig. 3A). CG-1 was the methylation "hot
spot" that was methylated in cancer cell lines and in tumors.
Our results showed a hypermethylated sequence in matched
tumor tissue samples compared with their normal counter-
parts (Fig. 3B). Similarly, prostate cancer cell lines were also
hypermethylated compared with the nonmalignant RWPE1
cell line (Fig. 3C). These results indicate that miR-23b is
silenced by hypermethylation in prostate cancer. To investi-
gate whethermiR-23bmethylation status affects its expression
in prostate cancer cell lines, we treated cells with the demethy-
lating agent 5-aza-deoxycitidine (5-Aza, 1 mmol/L) for 1 week
and then determined methylation status and miR-23b expres-
sion by methylation-speciﬁc qRT-PCR and qRT-PCR, respec-
tively. The methylation percentage in 5-Aza–treated cells was
signiﬁcantly decreased compared with untreated controls
along with a concomitant increase in miR-23b expression (Fig.
3C and D). To determine the correlation between percent
methylation of miR-23b and expression levels of its target Src
kinase, we analyzed the expression of miR-23b, Src kinase, and
the methylation of miR-23b in a different set of matched
patient samples (12 pairs). A negative correlationwas observed
between miR-23b and Src expression (P < 0.01), whereas a
positive correlation was found between percentage of meth-
ylation of miR-23b and Src expression (P < 0.03; Fig. 3H) in the
same patient samples.
To conﬁrm that promoter methylation is an important
mechanism of miR-23b suppression in patients with prostate
cancer, we investigated the correlation between methylation
status of miR-23b and its expression in the same samples.
Therewas a signiﬁcant inverse correlation between percentage
of methylation and miR-23b expression such that cases with
higher miR-23b expression had a lower percentage of meth-
ylation (P < 0.01; Fig. 3B and E; Supplementary Table S6).
Sequences of primers and probes are given in Supplementary
Table S7. We also conducted ROC analysis to evaluate the
percentage of miR-23b methylation to distinguish malignant
fromnormal cases inmatched tissue samples and cell lines. For
tissues, the AUC was 0.742 (P < 0.001; 95% CI, 0.575–0.870; Fig.
3G), whereas for cell lines (PC3 and DU145 vs. RWPE1), the
AUC was a perfect 1.00 (P < 0.000; 95% CI, 0.664–1.000; Fig. 3H),
indicating that miR-23b methylation can distinguish between
disease and normal cases.
miR-23b overexpression suppresses prostate cancer cell
proliferation, migration/invasion and colony formation
and induces G0–G1 cell-cycle arrest and apoptosis
We determined the functional signiﬁcance of miR-23b–
overexpressing prostate cancer. A signiﬁcant decrease in cell
proliferation was observed over time in miR-23b–transfected
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PC3 and DU145 cells (Fig. 4A) as compared with cells expres-
sing cont-miR. miR-23b–transfected cells also had low colony
formation ability, as the number of foci in miR-23b–expressing
cells was decreased when compared with cont-miR–trans-
fected cells (Fig. 4B; Supplementary Fig. S2). Less absorbance
was observed at 560 nm with miR-23b–transfected cells than
cont-miR in the migration assay (Fig. 4C), and miR-23b over-
expression also signiﬁcantly reduced the invasiveness of can-
cer cells (Fig. 4D). FACS analysis revealed that reexpression of
miR-23b leads to a signiﬁcant increase (22%–27%) in the
number of cells in the G0–G1 phase of the cell cycle, whereas
the S-phase population decreased from 19% to 20% to 4%,
suggesting that miR-23b causes a G0–G1 arrest in miR-23b–
transfected cells compared with controls (cont-miR; Fig. 4E).
FACS analysis for apoptosis was conducted using Annexin-V/
FITC/7-aminoactinomycin D (7-AAD) dye. The percentage
of total apoptotic cells (early apoptotic þ apoptotic) was
signiﬁcantly increased (13%–22%) in response to miR-23b
overexpression compared with cont-miR (3%–4%) with a
corresponding 13% to 20% decrease in the viable cell popula-
tion (Fig. 4F). Functional assays were also conducted in andro-
gen-dependent LNCaP cells, and the results were consistent
(Supplementary Fig. S3). These results indicate a tumor sup-
pressor role for miR-23b in prostate cancer.
miR-23b directly represses proto-oncogene Src kinase
and its downstream genes involved in proliferation/
survival/invasion and migration pathways in prostate
carcinoma
We investigated whether Src kinase is a direct functional
target of miR-23b in prostate cancer. Complimentary sites in
30UTR of Src kinase for miR-23b are given in Supplementary
Table S7. We chose Src kinase because it has been reported to
be a center stage molecule in cancer with pleiotropic effects
due to the multiple signaling pathways engaged by Src kinase
(Fig. 5A). In prostate cancer, Src kinase has been reported to be
involved in proliferation, migration, and invasion. Our results
showed that Src kinase is overexpressed in prostate cancer cell
lines compared with RWPE1 cells (Fig. 5B). Transient trans-
fection of humanprostate cancer cells with Src 30UTRplasmids
along with miR-23b led to a signiﬁcant decrease in relative
luciferase units when comparedwith SrcMut30UTR vector and
cont-miR or SrcMut30UTR vector andmiR-23b (Fig. 5C). These
results indicate that Src kinase is a direct target of miR-23b in
prostate cancer.
We next determined whether overexpression of miR-23b
regulates Src kinase at translational level and alters down-
stream signaling events. Transient transfection of prostate
cancer cells with miR-23b signiﬁcantly downregulated total
Src and active Src (pSrcY416) protein expression (Fig. 5D).
Western blot analysis showed reduced levels of downstream
molecules that are involved in proliferation, migration, and
invasion (Fig. 5E) in cells with suppressed Src expression
following miR-23b overexpression. Akt is an important down-
stream gene of Src. We found complimentary miR-23b binding
sequence in its 30UTR (Supplementary Table S7). Our results
showed that miR-23b can also directly target Akt (Supplemen-
tary Fig. S4). This further compliments our results thatmiR-23b
exerts its effects in prostate cancer, at least partly, through Src–
Akt pathway axis. We do not rule out the involvement of other
target genes ofmiR-23b action in prostate cancer, although our
results do indicate that Src–Akt axis pathway is partly involved.
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correlation of clinicopathologic characteristics with miR-23b expression. Group H L, miR-23b high or low.
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miR-23b downregulates EMT markers and suppresses
cellmigration and invasion independent of proliferation
To further show that the effect of miR-23b on cell migration
and invasion is an event independent of cell proliferation, we
examined the effect of overexpression of miR-23b on EMT
markers. A decrease in Vimentin and Slug (mesenchymal
markers) and an increase in E-cadherin (epithelial marker) was
observed inmiR-23b–transfected cells comparedwith the cont-
miR (Fig. 5F andG).Theprocess of EMT is involved in epithelial-
derived tumors causing them to become invasive and meta-
static. These results show that miR-23b suppressed EMT mar-
kers along with the other migratory/invasive genes such as Src
and focal adhesion kinase (FAK) and thus conﬁrm that effect of
miR-23b on invasion/migration is independent of proliferation.
Depletion of Src by RNA interference mimics miR-23b
reconstitution in prostate cancer
Phenocopy experiments were also carried out by siRNA
inhibition of Src (Fig. 6; Supplementary Fig. S5). We used a
validated siRNA that resulted in 80% to 90% Src gene
Figure 4. Transient transfection of miR-23b inhibits prostate cancer cell proliferation, colony formation, migration, invasion, and induces apoptosis and cell-
cycle arrest. A, proliferation of PC3 and DU145 cells after miR-23b transfection was signiﬁcantly reduced compared with cont-miR. B, miR-23b
overexpression signiﬁcantly inhibits colony-forming ability of prostate cancer cells. C,migration assays of PC3 and DU145 cells transfected withmiR-23b. D,
invasion assay shows a signiﬁcant decrease in the number of invading PC3 and DU145 cells transfected with miR-23b. E, cell-cycle analysis showing an
increase in the G0–G1 phase of PC3 and DU145 cells overexpressing miR-23b. F, apoptosis assay showing induction of apoptosis by miR-23b. , P < 0.05,
SD.
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knockdown at themRNAand protein levels (Fig. 6A) for further
experiments. Our results showed that siRNA inhibition of Src
increased G0–G1 cell-cycle population (16%–21%), whereas
there was a decrease of 11% to 12% in S-phase cell population
(Fig. 6B and C). Approximately 15% to 18% of the cells were in
the apoptotic fraction in Src siRNA–transfected cells com-
pared with 4% in nonspeciﬁc control (Fig. 6D and E). These
results suggest that inhibition of Src (that in turn depletes the
downstream Akt axis) by miR-23b overexpression is partly
responsible for the observed phenotype in prostate cancer
cells, and siRNA depletion of Src mimics the effect of miR-23b
Overexpression. We further carried out experiments with
antimiR-23b and anti-miR-Neg-control to determine whether
the protein expressions of the all the downregulated genes (by
miR-23b) are rescued. For this experiment, we chose DU145
cell line as it expresses higher levels of miR-23b than PC3.
Indeed the protein expression of all genes was rescued by anti-
miR-23b (Fig. 6F).
Intratumoral delivery of miR-23b suppresses
tumorigenicity in vivo
We also conducted in vivo growth suppression experiments
to determine the tumor-suppressive effect of miR-23b after
local administration in established tumors. Tumor growth was
Figure 5. miR-23b directly targets Src kinase and regulates downstream pathway genes and EMT. A, Src is a center stage molecule involved in various
pathways. B, Src kinase protein expression is high in prostate cancer cell lines than in nonmalignant RWPE1 cells. C, luciferase assays showing
decreased reporter activity after cotransfection of either wild-type Src-30UTR or its mutated 30UTR with miR-23b in PC3 and DU145 cells. Mut Src30UTR,
mutated 30UTR sequence. D, Western blot analysis showing miR-23b represses Src kinase translationally. E, Western blot analysis showing decreased
expression of Src kinase downstream genes. F and G, Western blotting and immunoﬂuorescence showing miR-23b downregulates EMT markers.
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signiﬁcantly suppressed by miR-23b over the course of exper-
iment compared with the cont-miR. Average tumor volume in
cont-miR was 850 mm3 compared with the average tumor
volumeof 38mm3 inmice that receivedmiR-23b (Fig. 7A) at the
termination of the experiment.We also checked the expression
of miR-23b or Src kinase in harvested tumors. Our results
showed that miR-23b expression was signiﬁcantly high with a
corresponding signiﬁcant decrease in the target Src kinase
gene expression in miR-23b–treated tumors compared with
controls (Fig. 7B and C). These results conﬁrm the tumor
suppressor effect of miR-23b in a prostate xenograft model.
Discussion
In this study, we found miR-23b to be signiﬁcantly silenced/
downregulated in human prostate tumor samples when com-
pared with adjacent normal samples. The downregulation of
miR-23b expression was also observed in prostate cancer cell
lines when compared with a nonmalignant cell line. This is
consistent with a previous miRNA proﬁling analysis of 9
prostate carcinoma samples and various cell lines that showed
downregulation of miR-23b (24). The suppression of miR-23b
expression in tumors and cancer cell lines suggests a tumor
suppressor role in prostate cancer. However, neither the
functional role nor the diagnostic or prognostic implications
of miR-23b in prostate cancer have been previously deﬁned.
DNA methylation–mediated downregulation of miRNAs by
proximal CpG islands has been described by a number of
groups (15, 25), and identiﬁcation of other targets for meth-
ylation may clarify the speciﬁc molecular events involved
in prostate cancer progression, enabling the prevention,
Figure 6. Depletion of Src kinase by
siRNA mimics miR-23b
overexpression. A, Src protein levels
were signiﬁcantly attenuated with 50
nmol/L Src-siRNA duplex (Si)
compared with a nonsilencing siRNA
duplex (Con). P, PC3; D, DU145. B
andC, cell-cycle analysis showing an
increase in the G0–G1 phase of PC3
and Du145 cells transfected with
siRNA. D and E, apoptosis assay
showing induction of apoptosis after
Src knockdown by siRNA in PC3 and
DU145 cells. , P < 0.05. F, Western
blot analysis showing the protein
expressions of Src, and its
downstream genes are rescued by
antimiR-23b transfection.
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diagnosis, and treatment of prostate cancer to be approached
at a molecular level. Here, we show that miR-23b is frequently
silenced through tumor-speciﬁc DNA methylation in prostate
cancer tissues and cell lines and themethylation can be used as
a diagnostic marker to distinguish malignant from normal
cases. miRNAs possess several features that make them attrac-
tive candidates as new prognostic biomarkers and powerful
tools for the early diagnosis of cancer (26). In this study, we
found that miR-23b was predictive of OS and RFS. Multiple
regression analysis also showed that miR-23b is an indepen-
dent predictor of biochemical recurrence. miR-23b expression
also distinguished malignant from normal tissues, indicating
the diagnostic signiﬁcance of miR-23b in prostate cancer.
An obstacle to understanding miRNA function has been the
relative lack of experimentally validated targets. We validated
Src kinase to be a direct target of miR-23b in prostate cancer.
Src kinase requires phosphorylation within a segment of the
kinase domain termed the activation loop for full catalytic
activity and this auto-phosphorylation site is tyrosine416 (27).
Src kinase has been reported to be activated in prostate cancer
(28, 29, 30). We showed that miR-23b inhibits Src kinase at
protein levels by directly binding to its 30UTR complimentary
sequences. Src is involved in multiple signaling pathways
including Ras/Raf/ERK1/2, PI3K/AKT, b-catenin/c-Myc/
cyclin D1, and FAK/p130CAS/MMP-9, and increased Src activ-
ity correlates with more aggressive phenotypes (28, 29, 31, 32).
We observed that inhibition of Src by miR-23b overexpression
reduced signaling via theMEK/ERK pathway. A previous study
by Chang and colleagues (28) has shown that Src inhibition by
small-molecule inhibitors induced apoptosis and cell-cycle
arrest at the G0–G1 phase of the cell cycle in prostate cancer
cell lines. Our results revealed that inhibition of Src bymiR-23b
overexpression induced apoptosis andG0–G1 arrest in prostate
cancer cells. This effect on the cell cycle and apoptosis
prompted us to study the effect on Src downstream target
genes AKT, BAD, and STAT3, a Src target and key transcrip-
tional factor for c-Myc and cyclin D1 (33) that are involved in
the G0–G1 phase of cell cycle. We found that all these genes
were downregulated at the protein level. Inhibition of Src has
been found to decrease the invasion and migration of prostate
cancer cells (29) through selective inhibition of Src substrates,
such as FAK. Our results indicate that miR-23b inhibited
prostate cell migration and invasion and also downregulated
c-Jun and FAK. Overexpression of miR-23b caused a decline in
the mesenchymal markers Vimentin and Snail, whereas there
was an increase in the expression of E-cadherin, an epithelial
marker. These results suggest that miR-23b suppresses migra-
tion and invasion independent of cell proliferation and that it
has an anti-metastatic effect on prostate cancer cells. To
determine whether Src inhibition is, at least partly, responsible
for the changes observed after miR-23b overexpression, we
carried out phenocopy experiments after inhibiting Src by
siRNA. Our results showed that inhibition of Src was respon-
sible for G0–G1 cell-cycle arrest, whereas there was a decrease
in S-phase cell population. Induction of apoptosis was also
observed in Src siRNA–transfected cells compared with non-
speciﬁc control. These results were similar to that of miR-23b
overexpression assays. We further determined that the protein
expressions of the genes that were downregulated by miR-23b
were rescued by antimiR-23b. These results strongly indicate
that the tumor-suppressive effect of miR-23b is, at least partly,
mediated by Src–Akt axis inhibition in prostate cancer.
The antiproliferative effects of miR-23b observed in this
study were conﬁrmed in prostate tumor xenograft models. In
conclusion, our study shows that miR-23b has an important
tumor suppressor role both in vitro and in vivo.
Accumulating evidence indicates thatmodulation ofmiRNA
also represents an attractive strategy for therapeutic gene
1,000
900
800
700
600
500
400
300
200
100
0
cont-miR
cont-miR
A
B C
miR-23b
miR-23b
cont-miR miR-23b
Src
GAPDH
C-1 C-2 23B-1 23B-2
24 27 30
8,000
7,000
6,000
5,000
4,000
3,000
2,000
1,000
0
33 36 39 42 45
Tu
m
o
r 
vo
lu
m
e 
(m
m3
)
R
el
at
ive
 m
iR
-2
3b
 e
xp
re
ss
io
n
Figure 7. miR-23b inhibit tumor
growth in vivo. ,P < 0.05. A, tumor
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silencing. miRNAs potentially inﬂuence cellular behavior
through the regulation of extensive gene expression networks.
Therapeutic modulation of a single miRNA may therefore
affect many pathways simultaneously to achieve clinical ben-
eﬁt. Our study is the ﬁrst report showing that miR-23b has
diagnostic/prognostic signiﬁcance and inhibits the Src–Akt
axis genes, a center stage pathway that regulates proliferation,
survival, and migration/invasion in cancer. It also highlights
the therapeutic potential of miR-23b in the treatment of
prostate cancer.
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